Halozyme Therapeutics (HALO) Institutional Ownership
13F filers reported holding 33.2% of Halozyme Therapeutics (HALO) shares as of Sep 30, 2026, across 457 filers.
- Held by 13F filers
- 33.2%
- Sep 30, 2026
- 13F filers
- 457
- quarter ended Sep 30, 2026
- 13F value
- $4.2B
- 37.9M shares
- Quarter's fund flow
- Mild accumulation
- 99 new · 25 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Acquired · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 4,810 | $108.18 | ↗ |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 3,090 | $108.91 | ↗ |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 11,900 | $110.00 | ↗ |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 200 | $110.51 | ↗ |
| Oct 8, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Acquired · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 8,600 | $111.03 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 10,300 | $111.84 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 900 | $112.78 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 200 | $113.69 | ↗ |
| Oct 7, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Acquired · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 2,300 | $107.90 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 6,000 | $109.33 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 9,920 | $109.89 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Open-market sale | 1,780 | $110.81 | ↗ |
| Oct 6, 2026 | Torley Helen | PRESIDENT AND CEO | Disposed · Option exercise | 20,000 | $18.41 | ↗ |
| Oct 1, 2026 | Daly James M | director | Acquired · Grant / award | 1,169Restricted Stock Units | — | ↗ |
| Oct 1, 2026 | Daly James M | director | Acquired · Grant / award | 1,775 | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Halozyme Therapeutics do institutions hold?
13F filers reported holding 33.2% of Halozyme Therapeutics' shares as of Sep 30, 2026, across 457 filers.
How many 13F filers hold Halozyme Therapeutics?
Halozyme Therapeutics was held by 457 13F filers as of Sep 30, 2026.
Not investment advice.

